However, more research is needed to determine if other chemotherapeuticagents are more effective than oxaliplatin used with HIPEC in this study and ifthere are certain subsets of patients who would still benefit from receivingHIPEC with surgery. Specifically, a subgroup analysis from this study suggestedthat HIPEC might be beneficial for patients with a mid-range peritoneal cancerindex (11–15), but the numbers were too small to be conclusive. People with alow peritoneal cancer index can likely forgo HIPEC, whereas those with a highindex may not benefit from either surgery or HIPEC.